Company News & Announcements

June 17, 2009

Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Liquid Filled Capsules

June 4, 2009

Xanodyne Announces New President/CEO and Completes $38 million equity financing

April 2, 2009

Xanodyne’s New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification

[ Corporate Governance ]

Xanodyne

Welcome to Xanodyne

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S.

Product Highlights

Oramorph SR

Oramorph is a sustained relief morphine oral tablet indicated for pain in patients who require opioid analgesia for more than a few days... [MORE]